{"entity":{"id":"nct04252859","kind":"trial","name":"[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma","aka":[],"tldr":"A phase 2 trial of FES PET in Breast cancer, run by University of Utah, recorded as terminated on the registry.","summary":"[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma is a phase 2 interventional study registered as NCT04252859 by University of Utah, with 44 participants recorded, started 2020-12-11 and due to reach its primary completion in 2024-12-07. Interventions recorded: [18F]Fluoroestradiol (FES) PET/CT. Conditions recorded: Invasive Lobular Breast Carcinoma.\n\nLinked to the technology FES PET because the registry's title names it (\"18f fluoroestradiol pet\") and Breast cancer among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04252859","url":"https://clinicaltrials.gov/study/NCT04252859"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":["fes-pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04252859","phase":"2","setting":"[18F]Fluoroestradiol-Positron Emission Tomography (PET)/CT Imaging of Invasive Lobular Carcinoma","sponsor":"University of Utah","started":"2020-12-11","startedType":"actual","yearReported":2025,"enrolled":44,"enrolledBasis":"registry","outcomes":[{"endpoint":"Positive Detection Rate of Invasive Lobular Carcinoma (ILC)","primary":true,"unit":"lesions","arms":[{"name":"Pilot Phase","n":17,"value":22,"note":"Figures from the ClinicalTrials.gov results section (first posted 2025-05-18), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT04252859?tab=results"},{"endpoint":"Relationship Between Presence of Heterogeneous FES-PET/CT Uptake at Baseline and Overall Survival","unit":"months","arms":[{"name":"Expansion Phase","n":3,"value":25.5,"note":"95% CI 21.67 to 46.82; Figures from the ClinicalTrials.gov results section (first posted 2025-05-18), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT04252859?tab=results"}]},"route":"/trials/nct04252859/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"invasive-lobular-carcinoma","kind":"cancer","name":"Invasive lobular carcinoma of the breast","route":"/cancers/invasive-lobular-carcinoma/"}],"technology":[{"id":"fes-pet","kind":"technology","name":"FES PET (oestrogen receptor imaging)","route":"/technologies/fes-pet/"}],"target":[{"id":"fes","kind":"target","name":"FES","route":"/targets/fes/"}]}}